<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01345279</url>
  </required_header>
  <id_info>
    <org_study_id>114016</org_study_id>
    <nct_id>NCT01345279</nct_id>
  </id_info>
  <brief_title>Indirect Comparison Topotecan Cervical Carcinoma</brief_title>
  <official_title>Indirect Comparison of the Efficacy Between Topotecan and Other Treatments for Recurrent Carcinoma of the Cervix</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Indirect comparisons were performed using data from GOG-0179 versus GOG-0169 to permit&#xD;
      comparison of topotecan in combination with cisplatin versus cisplatin plus paclitaxel via&#xD;
      the common comparator of cisplatin monotherapy. Both GOG-0179 and GOG-0169 were conducted in&#xD;
      patients with stage IVB, recurrent or persistent carcinoma of the cervix, but there were some&#xD;
      differences between the respective study populations. Patients with prior chemotherapy were&#xD;
      eligible for GOG-0179 but ineligible for GOG-0169 (except when chemotherapy was used for&#xD;
      radiation sensitisation). Fewer patients had received chemotherapy as a radiosensitiser in&#xD;
      GOG-0169 (27%) than in GOG-0179 (~60%) and these patients were unevenly distributed between&#xD;
      treatment arms in GOG-0169. In addition, the proportion of patients receiving cisplatin as a&#xD;
      radiosensitiser in GOG-0169 is unknown. For these reasons, there are limitations associated&#xD;
      with the indirect meta-analysis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">1</enrollment>
  <condition>Cervical Intraepithelial Neoplasia</condition>
  <arm_group>
    <arm_group_label>cisplatin</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>cisplatin + topotecan</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>cisplatin + paclitaxel</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>50 mg/m2 IV cisplatin on day 1 and then every 3 weeks for 6 courses</description>
    <arm_group_label>cisplatin</arm_group_label>
    <arm_group_label>cisplatin + paclitaxel</arm_group_label>
    <arm_group_label>cisplatin + topotecan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>topotecan</intervention_name>
    <description>topotecan 0.75 mg/m2 on days 1, 2, and 3. The regimen was repeated every 3 weeks for 6 courses</description>
    <arm_group_label>cisplatin + topotecan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <description>135 mg/m2 paclitaxel on day 1 and then every 3 weeks for 6 courses</description>
    <arm_group_label>cisplatin + paclitaxel</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The search was designed to identify all clinical data published since the Cancer Care&#xD;
        Ontario systematic review in 2006. The Cancer Care Ontario systematic review searched&#xD;
        MEDLINE (1966 to February 2006), EMBASE (1980 to February 2006), the Cochrane Library&#xD;
        (Cochrane Database of Systematic Reviews (2006 Issue 1), and Cochrane Controlled Trials&#xD;
        Register (2006 Issue 1)), the Canadian Medical Association Infobase, and the National&#xD;
        Guidelines Clearinghouse. The conference proceedings of the American Society of Clinical&#xD;
        Oncology (1995-2005) and the European Society of Medical Oncology (2002-2005) were also&#xD;
        searched. The search was completed on 18 December 2008&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  randomised clinical trials, or systematic reviews and meta-analyses&#xD;
&#xD;
          -  treatment with topotecan or platinum-based single and combination regimens in female&#xD;
             patients of any race with cancer of the cervix recurrent after radiotherapy or stage&#xD;
             IVB disease&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  None&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>July 16, 2010</study_first_submitted>
  <study_first_submitted_qc>April 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 2, 2011</study_first_posted>
  <last_update_submitted>May 25, 2017</last_update_submitted>
  <last_update_submitted_qc>May 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Topotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

